Ensysce Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M |
| Selling, general & administrative | — | — | — | — | $18.7M |
| Research and development | $10.4M | $7.2M | $7.6M | $19.8M | $4.7M |
| Operating expenses | $15.3M | $11.9M | $12.9M | $26.7M | $23.4M |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Interest expense | $18,767 | $1.3M | $353,945 | $109,525 | $1.3M |
| Net income | -$10.2M | -$8.0M | -$10.6M | -$24.2M | -$29.1M |
| Balance Sheet | |||||
| Cash and equivalents | $4.3M | $3.5M | $1.1M | $3.1M | $12.3M |
| Current assets | $7.2M | $5.3M | $2.3M | $5.3M | $15.7M |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M |
| Current liabilities | $4.6M | $2.2M | $3.3M | $9.5M | $16.5M |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M |
| Stockholders' equity | $3.2M | $3.7M | -$322,858 | -$3.7M | -$7.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M |
| Depreciation and amortization | $6,533 | $0 | $0 | $0 | $151 |
| Stock-based compensation | $177,086 | $110,723 | $879,160 | $1.1M | $121,764 |
| Capital expenditure | $123,643 | — | — | — | — |
| Free cash flow | -$7.9M | — | — | — | — |
Shares outstanding 14.7M · Free float 6.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.